Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + FOLFIRI + curcumin
- Development stage
- Unknown
- Lead developer
- Gachon University Gil Medical Center
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen consists of the monoclonal antibody bevacizumab (Avastin), the FOLFIRI chemotherapy backbone (folinic acid, fluorouracil, and irinotecan), and an oral curcumin-containing supplement. Bevacizumab is an angiogenesis inhibitor that targets vascular endothelial growth factor (VEGF). FOLFIRI is a standard cytotoxic regimen where irinotecan inhibits topoisomerase I and fluorouracil (potentiated by folinic acid) inhibits thymidylate synthase to disrupt DNA synthesis. The addition of a ginsenoside-modified nanostructured lipid carrier containing curcumin (G-NLC) is intended to provide complementary anti-tumor and anti-inflammatory activity. This specific regimen was evaluated in a Phase 2 clinical trial (NCT02439385) led by Gachon University Gil Medical Center for the first-line treatment of patients with unresectable metastatic colorectal cancer.
- Brand names
- Avastin
- Other names
- Avastin/FOLFIRI and Curcuminbevacizumab + folinic acid + fluorouracil + irinotecan + curcumin
02
Targets
Beyond the preview
Go deeper on bevacizumab + FOLFIRI + curcumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + FOLFIRI + curcumin.